1
|
Ahmed F, Gi Ho S, Samantasinghar A, Memon FH, Rahim CSA, Soomro AM, Pratibha, Sunildutt N, Kim KH, Choi KH. Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles. Comput Struct Biotechnol J 2022; 20:6097-6107. [DOI: 10.1016/j.csbj.2022.10.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2022] [Revised: 10/09/2022] [Accepted: 10/30/2022] [Indexed: 11/10/2022] Open
|
2
|
Bian G, Wang L, Xie Q, Wang Y, Feng H, Yu Y, Chen Z, Deng S, Li Y. DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation. Br J Pharmacol 2020; 178:636-653. [PMID: 33140855 DOI: 10.1111/bph.15306] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 08/24/2020] [Accepted: 10/21/2020] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND AND PURPOSE Psoriasis is a chronic immune-mediated inflammatory skin disease that easily recurs and is difficult to cure. DGT is a novel synthetic heterocyclic diterpenoid, whose structure has not been previously reported. We have investigated the action of DGT against psoriasis, specifically the hyperproliferation of epidermal keratinocytes, angiogenesis and pathogenic inflammatory responses. EXPERIMENTAL APPROACH We investigated its pharmacokinetics in skin after topical administration. We characterized its pharmacological actions in vitro and in vivo using cell proliferation assay, cell apoptosis assay, diethylstilbestrol-induced mouse vaginal epithelial cell mitosis model, tube formation assay, cell migration assay, chick embryonic chorioallantoic membrane (CAM) assay, histological, flow cytometric analysis and imiquimod (IMQ)-induced psoriasis-like model. KEY RESULTS DGT was found to be mainly distributed in the epidermis and dermis, which indicated that DGT was suitable as a topical treatment. DGT inhibited cell proliferation and induced apoptotic cell death of keratinocytes in vitro and in vivo. Moreover, DGT inhibited endothelial cell proliferation, tube formation and migration of in vitro angiogenesis, as well as in vivo CAM angiogenesis. In an IMQ-induced psoriasis-like skin inflammation murine model, topical application of DGT ameliorated keratinocyte proliferation and inflammatory response, especially in IL-17-related psoriasiform dermatitis. Furthermore, our results demonstrated that DGT prevented these pathological processes of psoriasis through suppression of STAT3 phosphorylation. CONCLUSION AND IMPLICATIONS DGT has great potential as a novel therapeutic agent for the treatment of psoriatic skin disease.
Collapse
Affiliation(s)
- Gang Bian
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Lidan Wang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Qing Xie
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Yanping Wang
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| | - Haimei Feng
- Department of Pharmacology, Suzhou Pharmavan Co., Ltd, Suzhou, China
| | - Yunhui Yu
- Department of Pharmacology, Suzhou Pharmavan Co., Ltd, Suzhou, China
| | - Zijun Chen
- School of Basic Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
| | - Shiping Deng
- Department of Pharmacology, Suzhou Pharmavan Co., Ltd, Suzhou, China
| | - Yunsen Li
- Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China
| |
Collapse
|
3
|
Clarysse K, Pfaff CM, Marquardt Y, Huth L, Kortekaas Krohn I, Kluwig D, Lüscher B, Gutermuth J, Baron J. JAK1/3 inhibition preserves epidermal morphology in full-thickness 3D skin models of atopic dermatitis and psoriasis. J Eur Acad Dermatol Venereol 2019; 33:367-375. [PMID: 30357932 DOI: 10.1111/jdv.15301] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 09/19/2018] [Indexed: 12/30/2022]
Abstract
BACKGROUND Janus kinase (JAK) inhibition may be a promising new treatment modality for inflammatory (skin) diseases. However, little is known about direct effects of kinase inhibitors on keratinocyte differentiation and function as well as skin barrier formation. OBJECTIVE Our aim was to address the direct impact of kinase inhibition of the JAK1/3 pathways by tofacitinib on keratinocyte immune function and barrier formation in atopic dermatitis (AD) and psoriasis. METHODS 3D skin equivalents of both diseases were developed and concurrently pretreated with tofacitinib. To induce AD, 3D skin equivalents were stimulated with recombinant human IL-4 and IL-13. Psoriasis-like conditions were induced by incubation with IL-17A, IL-22 and tumour necrosis factor α (TNFα). The activation of signal transducer and activator of transcription (STAT)1, STAT3 and STAT6 was assessed by Western blot analysis. Microarray analysis and quantitative real-time PCR were used for gene expression analysis. RESULTS Tofacitinib pretreatment preserved epidermal morphology and reduced STAT3 and STAT6 phosphorylation of AD-like and STAT3 phosphorylation of psoriasis-like culture conditions in 3D skin models compared to sham-controls. Filaggrin expression was fully maintained in the AD-like models, but only partially in psoriasis-like conditions after pretreatment with tofacitinib. In addition, tofacitinib upregulated DSC1, FLG and KRT1. Using gene expression analysis, downregulation of POSTN and IL24 was observed in AD-like conditions, whereas downregulation of IL20 and IL1B was observed in psoriasis-like conditions. CONCLUSION JAK1/3 inhibition counteracted cytokine-induced AD- and psoriasis-like epidermal morphology and enhanced keratinocyte differentiation in 3D skin models. This effect was more pronounced in the AD-like models compared to the psoriasis-like 3D skin models.
Collapse
Affiliation(s)
- K Clarysse
- Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium
| | - C M Pfaff
- Department of Dermatology and Allergology, Medical School, RWTH Aachen University, Aachen, Germany.,Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Aachen, Germany
| | - Y Marquardt
- Department of Dermatology and Allergology, Medical School, RWTH Aachen University, Aachen, Germany
| | - L Huth
- Department of Dermatology and Allergology, Medical School, RWTH Aachen University, Aachen, Germany
| | - I Kortekaas Krohn
- Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium
| | - D Kluwig
- Department of Dermatology and Allergology, Medical School, RWTH Aachen University, Aachen, Germany
| | - B Lüscher
- Institute of Biochemistry and Molecular Biology, Medical School, RWTH Aachen University, Aachen, Germany
| | - J Gutermuth
- Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Dermatology, Brussels, Belgium
| | - J Baron
- Department of Dermatology and Allergology, Medical School, RWTH Aachen University, Aachen, Germany
| |
Collapse
|
4
|
van den Reek J, Seyger M, van Lümig P, Driessen R, Schalkwijk C, Berends M, van de Kerkhof P, de Jong E. The journey of adult psoriasis patients towards biologics: past and present - Results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol 2017; 32:615-623. [DOI: 10.1111/jdv.14684] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2017] [Accepted: 10/20/2017] [Indexed: 02/06/2023]
Affiliation(s)
| | - M.M.B. Seyger
- Department of Dermatology; Radboudumc; Nijmegen The Netherlands
| | | | - R.J.B. Driessen
- Department of Dermatology; Radboudumc; Nijmegen The Netherlands
| | | | - M.A.M. Berends
- Department of Dermatology; Slingeland Hospital; Doetinchem The Netherlands
| | | | - E.M.G.J. de Jong
- Department of Dermatology; Radboudumc; Nijmegen The Netherlands
- Radboud University; Nijmegen The Netherlands
| |
Collapse
|
5
|
Wang D, Gu J, Zhu W, Luo F, Chen L, Xu X, Lu C. PDTCM: a systems pharmacology platform of traditional Chinese medicine for psoriasis. Ann Med 2017; 49:652-660. [PMID: 28782992 DOI: 10.1080/07853890.2017.1364417] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
INTRODUCTION Psoriasis is a refractory skin disorder, and usually requires a lifetime control. Traditional Chinese medicine (TCM) is effective and safe for this disease. However, the cellular and molecular mechanisms of TCM remedies for psoriasis are still not fully understood. TCM contains numerous natural products. Natural products have historically been invaluable as a resource of therapeutic agents. Yet, there is no integrated information about active compounds of TCM for psoriasis. METHOD We use systems pharmacology methods to develop the Psoriasis Database of Traditional Chinese Medicine (PDTCM). The database covered a number of psoriasis-related information (formulas, TCM, compounds, target proteins, diseases and biomarkers). With these data information, an online platform was constructed Results: PDTCM comprises 38 empirical therapeutic formulas, 34373 compounds from 1424 medicinal plants, 44 psoriasis-related proteins and 76 biomarkers from 111 related diseases. On this platform, users can screen active compounds for a psoriasis-related target and explore molecular mechanisms of TCM. Accordingly, users can also download the retrieved structures and data information with a defined value set. In addition, it helps to get a better understanding of Chinese prescriptions in disease treatment. CONCLUSION With the systems pharmacology-based data, PDTCM would become a valuable resource for TCM in psoriasis-related research. Key messages PDTCM platform comprises a great deal of data on TCM and psoriasis. On this platform, users can retrieve and get needed information with systems pharmacology methods, such as active compounds screening, target prediction and molecular mechanisms exploration. It is a tool for psoriasis-related research on natural drugs systematically.
Collapse
Affiliation(s)
- Dongmei Wang
- a The Second Institute of Clinical Medicine , Guangzhou University of Chinese Medicine , Guangzhou , China.,b Lab of Chinese Materia Medica Preparation , Guangdong Provincial Academy of Chinese Medical Sciences , Guangzhou , China.,c Postdoctoral Research Station , Guangzhou University of Chinese Medicine , Guangzhou , China
| | - Jiangyong Gu
- a The Second Institute of Clinical Medicine , Guangzhou University of Chinese Medicine , Guangzhou , China.,b Lab of Chinese Materia Medica Preparation , Guangdong Provincial Academy of Chinese Medical Sciences , Guangzhou , China
| | - Wei Zhu
- a The Second Institute of Clinical Medicine , Guangzhou University of Chinese Medicine , Guangzhou , China.,b Lab of Chinese Materia Medica Preparation , Guangdong Provincial Academy of Chinese Medical Sciences , Guangzhou , China
| | - Fang Luo
- d Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering , Peking University , Beijing , China
| | - Lirong Chen
- d Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering , Peking University , Beijing , China
| | - Xiaojie Xu
- b Lab of Chinese Materia Medica Preparation , Guangdong Provincial Academy of Chinese Medical Sciences , Guangzhou , China.,d Beijing National Laboratory for Molecular Sciences (BNLMS), State Key Laboratory of Rare Earth Materials Chemistry and Applications, College of Chemistry and Molecular Engineering , Peking University , Beijing , China
| | - Chuanjian Lu
- a The Second Institute of Clinical Medicine , Guangzhou University of Chinese Medicine , Guangzhou , China.,b Lab of Chinese Materia Medica Preparation , Guangdong Provincial Academy of Chinese Medical Sciences , Guangzhou , China.,e Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome , Guangzhou , China
| |
Collapse
|
6
|
Rigante D. New mosaic tiles in childhood hereditary autoinflammatory disorders. Immunol Lett 2017; 193:67-76. [PMID: 29198619 DOI: 10.1016/j.imlet.2017.11.013] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2017] [Accepted: 11/29/2017] [Indexed: 12/21/2022]
Abstract
The protean clinical phenotypes of hereditary autoinflammatory disorders (HAID) are caused by abnormal activation of innate immunity and consist of seemingly unprovoked inflammatory flares localized to multiple organs, such as the skin, joints, serosal membranes, gut, and central nervous system. Different mutations in genes implied in activation of the interleukin-1 (IL-1)-structured inflammasome, cytoskeletal signaling and apoptosis contribute to the pathogenesis of different HAID, which mostly start in childhood with self-limited flares unrelated to infectious agents, autoantibody production or autoreactive cells. Though IL-1 remains pivotal in many inflammasome-mediated diseases, other cytokinopathies involving IL-18, nuclear factorκ-B, interferons, and tumor necrosis factor have provided new horizons in the definition of HAID of children: the list of HAID has expanded as a consequence of a better understanding of their pathogenetic molecular mechanisms and also application of new genetic technologies. However, diagnosis of most HAID is clinical and focused on several evidence-based criteria sets: their discrimination remains challenging for unexperienced pediatricians as there are no universally accepted algorithms, and a still relevant number of patients may linger without any clarifying genetic analysis, whose interpretation combined with processing of treatment options should be discussed on a multidisciplinary basis.
Collapse
Affiliation(s)
- Donato Rigante
- Institute of Pediatrics, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica Sacro Cuore, Rome, Italy.
| |
Collapse
|
7
|
Sharma M, Levenson C, Clements I, Castella P, Gebauer K, Cox ME. East Indian Sandalwood Oil (EISO) Alleviates Inflammatory and Proliferative Pathologies of Psoriasis. Front Pharmacol 2017; 8:125. [PMID: 28360856 PMCID: PMC5352686 DOI: 10.3389/fphar.2017.00125] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2016] [Accepted: 02/28/2017] [Indexed: 12/21/2022] Open
Abstract
Psoriasis, a chronic inflammatory skin disease marked by hyper proliferation and aberrant differentiation of keratinocytes, affects 2–3% of the world’s population. Research into the pathogenesis of psoriasis has been hampered by the lack of models that accurately reflect the biology of the psoriatic phenotype. We have previously reported that East Indian Sandalwood oil (EISO) has significant anti-inflammatory properties in skin models and hypothesized that EISO might provide therapeutic benefit to psoriasis patients due to its anti-inflammatory and anti-proliferative properties. Here we present interim results from an on-going proof-of-concept Phase 2 clinical trial in which topically applied EISO is demonstrating to be well tolerated and helpful in alleviating mild to moderate psoriasis symptoms. This led us to evaluate the ability of EISO to affect the psoriatic phenotype using MatTek Corporation reconstituted organotypic psoriatic and normal human skin models. EISO had no impact on the phenotype of the normal skin tissue model, however, EISO treatment of the psoriasis tissue model reverted psoriatic pathology as demonstrated by histologic characterization and expression of keratinocyte proliferation markers, Ki67 and psoriasin. These phenotypic affects correlated with suppressed production of ENA-78, IL-6, IL-8, MCP-1, GM-CSF, and IL-1β. Demonstration of the ability of EISO to abrogate these psoriasis symptoms in well-characterized in vitro psoriatic tissue models, supports the hypothesis that the clinically observed symptom alleviation is due to suppression of intrinsic tissue inflammation reactions in afflicted lesions. This study presents a systematic approach to further study the underlying mechanisms that cause psoriasis, and presents data supporting the potential of EISO as a new ethnobotanical therapeutic concept to help direct and accelerate the development of more effective therapies.
Collapse
Affiliation(s)
- Manju Sharma
- The Vancouver Prostate Centre, Vancouver BC, Canada
| | | | - Ian Clements
- Santalis Pharmaceuticals, Inc., San Antonio TX, USA
| | | | | | | |
Collapse
|
8
|
Torres T, Filipe P. Small Molecules in the Treatment of Psoriasis. Drug Dev Res 2015; 76:215-27. [DOI: 10.1002/ddr.21263] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 07/14/2015] [Indexed: 12/27/2022]
Affiliation(s)
- Tiago Torres
- Department of Dermatology; Centro Hospitalar do Porto; Portugal
- Instituto de Ciências Biomédicas Abel Salazar; University of Porto; Portugal
| | - Paulo Filipe
- Dermatology Research Unit, Instituto de Medicina Molecular; University of Lisbon; Portugal
| |
Collapse
|
9
|
Abstract
Psoriasis is a common chronic inflammatory skin disease with a spectrum of clinical phenotypes and results from the interplay of genetic, environmental, and immunological factors. Four decades of clinical and basic research on psoriasis have elucidated many of the pathogenic mechanisms underlying disease and paved the way to effective targeted therapies. Here, we review this progress and identify future directions of study that are supported by a more integrative research approach and aim at further improving the patients' life.
Collapse
Affiliation(s)
- Paola Di Meglio
- Molecular Immunology, Medical Research Council National Institute for Medical Research, London NW7 1AA, United Kingdom
| | - Federica Villanova
- St. John's Institute of Dermatology, King's College London, London SE1 9RT, United Kingdom National Institute for Health Research GSTT/KCL Comprehensive Biomedical Research Centre, Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom
| | - Frank O Nestle
- St. John's Institute of Dermatology, King's College London, London SE1 9RT, United Kingdom National Institute for Health Research GSTT/KCL Comprehensive Biomedical Research Centre, Guy's and St. Thomas' National Health Service Foundation Trust, London SE1 9RT, United Kingdom
| |
Collapse
|